Table 2.
Characteristics of laboratory markers of nephrotoxicity, liver damage, and bone marrow toxicity in included osteosarcoma patients.
| Measurement (in plasma) | Mean (SD) or median (range)* | Number of datapoints (of number of patients) |
|---|---|---|
| MTX level (t = 48 h), µmol/L | 0.25 (0.05–82.34) | 1238 (113) |
| Creatinine levels (t = 48 h), µmol/L | 48.2 (15.1) | 551 (91) |
| Creatinine levels (t = week 1), µmol/L | 51.7 (17.9) | 857 (110) |
| ALAT levels (t = 48 h), U/L | 260 (10–4,677) | 475 (87) |
| ASAT levels (t = 48 h), U/L | 106 (11–4,420) | 461 (87) |
| Hemoglobin levels (t = week 1), mmol/L | 6.5 (0.8) | 908 (112) |
| Thrombocyte counts (t = week 1), x 103/mm³ | 184 (10–740) | 896 (112) |
| Leukocyte counts (t = week 1), x 109/L | 4.4 (0.8–38.2) | 905 (112) |
| Neutrophil counts (t = week 1), x 109/L | 2.3 (0.0–35.8) | 709 (109) |
*Mean and standard deviation (SD) for normally distributed data, median and range for other.